Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pyrimidine Triones as Potential Activators of p53 Mutants.

Biomolecules - 8 Aug 2024

Fallatah Maryam M Jebril, Demir Özlem, Law Fiona, Lauinger Linda, Baronio Roberta, Hall Linda, Bournique Elodie, Srivastava Ambuj, Metzen Landon Tyler, Norman Zane, Buisson Rémi, Amaro Rommie E, Kaiser Peter

Abstract excerpt

p53 is a crucial tumor suppressor in vertebrates that is frequently mutated in human cancers. Most mutations are missense mutations that render p53 inactive in suppressing tumor initiation and progression. Developing small-molecule drugs to convert mutant p53 into an active, wild-type-like conformation is a significant focus for personalized cancer therapy. Prior research indicates that reactivating p53...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Proliferation

Share to Mutation

Share to Neoplasms

Share to Pyrimidines

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 39199355
DOI: 10.3390/biom14080967
PMCID: PMC11352488

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pyrimidine Triones as Potential Activators of p53 Mutants.PMID 39199355Read ↗

Discovery of compounds that reactivate p53 mutants in vitro and in vivo.Semantic proximity Read ↗

A selective p53 activator and anticancer agent to improve colorectal cancer therapySemantic proximity Read ↗

Pharmacological reactivation of mutant p53: from protein structure to the cancer patient.Semantic proximity Read ↗

Mutant p53 reactivation by small molecules makes its way to the clinic.Semantic proximity Read ↗

Targeting Oncogenic Mutant p53 for Cancer TherapySemantic proximity Read ↗

Activating p53 <sup>Y220C</sup> with a Mutant-Specific Small MoleculeSemantic proximity Read ↗

The p53 Pathway as a Target in Cancer Therapeutics: Obstacles and PromiseSemantic proximity Read ↗

Discovery of Rezatapopt (PC14586), a First-in-Class, Small-Molecule Reactivator of p53 Y220C Mutant in DevelopmentSemantic proximity Read ↗

Small-Molecule Reactivation of Mutant p53 to Wild-Type-like p53 through the p53-Hsp40 Regulatory Axis.Semantic proximity Read ↗

Activating p53Y220C with a mutant-specific small molecule.Semantic proximity Read ↗

Restoration of the Tumor Suppressor Function of Y220C-Mutant p53 by Rezatapopt, a Small-Molecule ReactivatorSemantic proximity Read ↗

A Small Molecule Reacts with the p53 Somatic Mutant Y220C to Rescue Wild-type Thermal Stability.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.